Hospira Tops on All Fronts - Analyst Blog
07 Novembro 2012 - 9:32AM
Zacks
Hospira Inc.’s (HSP) third quarter 2012
earnings (excluding special items) of 47 cents per share beat the
Zacks Consensus Estimate of 45 cents. Higher than expected revenues
led to the earnings beat. However, earnings fell short of the
year-ago figure by 28.8%.
On a reported basis (including special items), the company earned 1
cent per share as opposed to the year-ago loss of 54 cents per
share.
The Lake Forest, Illinois-based company came up with revenues of
$994 million in the reported quarter, beating the Zacks Consensus
Estimate of $990 million. Revenues were 1.8% higher than the
year-ago figure driven by strong sales of key drugs in the
Specialty Injectable Pharmaceuticals (SIP) business at Hospira.
Quarter in Details
The SIP business, the biggest contributor to Hospira’s revenues,
performed well in the quarter with sales from the segment climbing
2.6% (up 4.9% at constant currency) to $643.2 million.
Drugs such as Precedex performed well during the quarter. Moreover,
the August 2012 re-launch of Hospira’s generic version of
Sanofi’s (SNY) cancer drug, Eloxatin, also aided
results. The SIP segment includes generic injectables as well as
proprietary specialty injectables.
Sales in the Medication Management segment declined 1.7% (up 0.5%
at constant currency) to $236.6 million. Sales in the Other Pharma
division climbed 4.5% (up 5.6% at constant currency) to $114.2
million.
Geographically, the Americas, Europe, Middle East and Africa and
the Asia-Pacific markets contributed $789.1 million (up 3.6% at
constant currency), $122.9 million (up 5.2% at constant currency)
and $82.0 million (up 4.9% at constant currency), respectively, to
total revenue in the reported quarter.
2012 Outlook
The company continues to expect top-line growth in the range of -1%
to 2% on a constant currency basis. Foreign exchange is expected to
negatively impact the top line by 1 to 2%. The company expects 2012
adjusted earnings of $2.00 per share. The Zacks Consensus Estimate
for 2012 too stands at $2.00 per share.
Hospira now expects cash flow from operations in the range of
$475-$500 million (previous guidance: $475-$525 million) in
2012. The company now expects capital expenditures in the
range of $325-$350 million (previous guidance: $350-$400 million).
Depreciation and amortization continues to be projected in the
range of $240-$260 million.
Neutral on Hospira
Currently, we have a long-term Neutral recommendation on Hospira.
The stock carries a Zacks #3 Rank (Hold rating) in the short
run.
HOSPIRA INC (HSP): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024
Notícias em tempo-real sobre da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Hospira